Newswise — The University of Maryland, Baltimore (UMB) announced today it will participate in the BIO 2008 International Convention, June 17 - 20, 2008, in San Diego, Calif.
UMB President David J. Ramsay, DM, DPhil, and members of his senior staff will meet with biotechnology and pharmaceutical companies about commercializing more than 100 new technologies, forming collaborative research and conducting clinical trials.
UMB is among the top ten public academic medical centers in the country. In the past decade, the university increased its research base from $138 million to $411 million, leading to an escalation in entrepreneurial spirit. With about 20,000 employees including the University of Maryland Medical Center, the university consists of schools of dentistry, law, medicine, nursing, pharmacy, dentistry, law, public health, and social work.
The team will also confer with prospective companies for the rapidly expanding University of Maryland BioPark... Only five years in development, with the first two of a projected 10 research buildings completed, the BioPark, located in downtown Baltimore, is occupied by several early and later stage companies, including SNBL Clinical Pharmacology Center, Inc.; Alba Therapeutics Corp; FASgen, LLC; IRAZÚ BioDiscovery, LLC and Acidophil, Inc. UMB and many of the BioPark tenants will exhibit in the Maryland Pavilion at the Convention.
The convention is an annual event held at different locations throughout the U.S. and hosted by the Biotechnology Industry Organization. BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,150 members worldwide.
RSS